It's interesting that the drug in the article targets cancer stem cells and mentions this is an old theory that hasn't gotten that much traction due to multiple failures with other companies in p2. Would seem this 'deal' has benchmarks that determine dollar amount rewarded for success all through the expanded testing. If it fails as all have to date, it's possible the deal could be worth less than the splashy headlines. Still, to have a deal in hand is a mighty success story and one to hope that Leo negotiates in the near future. Funding for all of B and K applications and P would be a 360 slam dunk and the pps in orbit.